{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:35:31Z","timestamp":1770964531485,"version":"3.50.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>Previous studies on the<jats:italic toggle=\"yes\">N<\/jats:italic>-phenylpiperazine derivative LASSBio-579 have suggested that LASSBio-579 has an atypical antipsychotic profile. It binds to D<jats:sub>2<\/jats:sub>, D<jats:sub>4<\/jats:sub>and 5-HT<jats:sub>1A<\/jats:sub>receptors and is effective in animal models of schizophrenia symptoms (prepulse inhibition disruption, apomorphine-induced climbing and amphetamine-induced stereotypy). In the current study, we evaluated the effect of LASSBio-579, clozapine (atypical antipsychotic) and haloperidol (typical antipsychotic) in the novel object recognition task, a recognition memory model with translational value. Haloperidol (0.01\u2009mg\/kg, orally) impaired the ability of the animals (CF1 mice) to recognize the novel object on short-term and long-term memory tasks, whereas LASSBio-579 (5\u2009mg\/kg, orally) and clozapine (1\u2009mg\/kg, orally) did not. In another set of experiments, animals previously treated with ketamine (10\u2009mg\/kg, intraperitoneally) or vehicle (saline 1\u2009ml\/100\u2009g, intraperitoneally) received LASSBio-579, clozapine or haloperidol at different time-points: 1\u2009h before training (encoding\/consolidation); immediately after training (consolidation); or 1\u2009h before long-term memory testing (retrieval). LASSBio-579 and clozapine protected against the long-term memory impairment induced by ketamine when administered at the stages of encoding, consolidation and retrieval of memory. These findings point to the potential of LASSBio-579 for treating cognitive symptoms of schizophrenia and other disorders.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000200","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T10:43:32Z","timestamp":1446115412000},"page":"339-349","source":"Crossref","is-referenced-by-count":7,"title":["LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model"],"prefix":"10.1097","volume":"27","author":[{"given":"Camila B.","family":"Antonio","sequence":"first","affiliation":[{"name":"Post Graduate Program in Pharmaceutical Sciences, Department of Raw Material Production, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andresa H.","family":"Betti","sequence":"additional","affiliation":[{"name":"Post Graduate Program in Pharmaceutical Sciences, Department of Raw Material Production, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Herzfeldt","sequence":"additional","affiliation":[{"name":"Post Graduate Program in Pharmaceutical Sciences, Department of Raw Material Production, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliezer J.","family":"Barreiro","sequence":"additional","affiliation":[{"name":"Laboratory of Evaluation and Synthesis of Bioactive substances, Department of Pharmaceuticals, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.M.","family":"Fraga","sequence":"additional","affiliation":[{"name":"Laboratory of Evaluation and Synthesis of Bioactive substances, Department of Pharmaceuticals, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela M.K.","family":"Rates","sequence":"additional","affiliation":[{"name":"Post Graduate Program in Pharmaceutical Sciences, Department of Raw Material Production, Federal University of Rio Grande do Sul, Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230910","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10339-011-0430-z","article-title":"The novel object recognition memory: neurobiology, test procedure and its modifications","volume":"13","author":"Antunes","year":"2012","journal-title":"Cogn Process"},{"key":"R2-20230910","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)37013-2","article-title":"Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro","volume":"283","author":"Arvanov","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R3-20230910","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J Psychopharmacol"},{"key":"R4-20230910","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R5-20230910","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/ALN.0b013e318219524e","article-title":"Anesthetic ketamine impairs rats\u2019 recall of previous information: the nitric oxide synthase inhibitor N-nitro-l-arginine methylester antagonizes this ketamine-induced recognition memory deficit","volume":"114","author":"Boultadakis","year":"2011","journal-title":"Anesthesiology"},{"key":"R6-20230910","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archpsyc.1990.01810140081011","article-title":"Sensorimotor gating and schizophrenia. Human and animal model studies","volume":"47","author":"Braff","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"R7-20230910","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-20230910","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS Workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr Bull"},{"key":"R10-20230910","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/schbul\/sbm083","article-title":"Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr Bull"},{"key":"R12-20230910","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1196\/annals.1300.020","article-title":"Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia","volume":"1003","author":"Coyle","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R13-20230910","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.neubiorev.2007.01.005","article-title":"The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents","volume":"31","author":"Dere","year":"2007","journal-title":"Neurosci Biobehav Rev"},{"key":"R14-20230910","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bbr.2009.12.036","article-title":"One-trial object recognition in rats and mice: methodological and theoretical issues","volume":"215","author":"Ennaceur","year":"2010","journal-title":"Behav Brain Res"},{"key":"R15-20230910","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1. Behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav Brain Res"},{"issue":"2\u20133","key":"R16-20230910","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-9964(02)00168-8","article-title":"Visual object processing in schizophrenia: evidence for an associative agnosic deficit","volume":"59","author":"Gabrovska","year":"2003","journal-title":"Schizophr Res"},{"key":"R17-20230910","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/schbul\/sbi057","article-title":"New approaches to measurement and treatment research to improve cognition in schizophrenia","volume":"31","author":"Geyer","year":"2005","journal-title":"Schizophr Bull"},{"key":"R18-20230910","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejmech.2012.08.011","article-title":"Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound","volume":"62","author":"Gomes","year":"2013","journal-title":"Eur J Med Chem"},{"key":"R19-20230910","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neuroscience.2010.03.032","article-title":"Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels","volume":"167","author":"Goulart","year":"2010","journal-title":"Neuroscience"},{"key":"R20-20230910","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","article-title":"Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat","volume":"184","author":"Grayson","year":"2007","journal-title":"Behav Brain Res"},{"key":"R22-20230910","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R23-20230910","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbr.2007.07.033","article-title":"D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats","volume":"186","author":"Karasawa","year":"2008","journal-title":"Behav Brain Res"},{"key":"R24-20230910","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R25-20230910","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00213-011-2536-5","article-title":"Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models","volume":"220","author":"Lyon","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"R26-20230910","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/S0968-0896(03)00487-5","article-title":"Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands","volume":"11","author":"Menegatti","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"R27-20230910","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.lfs.2006.07.004","article-title":"Effects of beta-carboline alkaloids on the object recognition task in mice","volume":"79","author":"Moura","year":"2006","journal-title":"Life Sci"},{"key":"R28-20230910","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet"},{"key":"R29-20230910","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.nlm.2007.10.002","article-title":"On the participation of mTOR in recognition memory","volume":"89","author":"Myskiw","year":"2008","journal-title":"Neurobiol Learn Mem"},{"issue":"1\u20133","key":"R30-20230910","first-page":"315","article-title":"Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors","volume":"202","author":"Nagai","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R31-20230910","author":"Neves","year":"2009"},{"key":"R32-20230910","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1590\/S0100-879X2003000500010","article-title":"Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives","volume":"36","author":"Neves","year":"2003","journal-title":"Braz J Med Biol Res"},{"key":"R33-20230910","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pbb.2007.10.018","article-title":"Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiprazine antipsychotic prototypes LASSBio-579 and LASSBio-581","volume":"89","author":"Neves","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"R34-20230910","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bmc.2010.01.040","article-title":"Searching for multi-target antipsychotics: discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors","volume":"18","author":"Neves","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"R35-20230910","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbr.2012.09.016","article-title":"New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia","volume":"237","author":"Neves","year":"2013","journal-title":"Behav Brain Res"},{"key":"R36-20230910","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","article-title":"Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties","volume":"216","author":"Newman-Tancredi","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R38-20230910","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr Res"},{"key":"R39-20230910","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/jpet.110.166710","article-title":"Behavioral indices in antipsychotic drug discovery","volume":"333","author":"Porsolt","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R40-20230910","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1476-5381.2011.01638.x","article-title":"Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes","volume":"165","author":"Tanahashi","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R41-20230910","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/j.1440-1614.2005.01626.x","article-title":"Importance of animal models in schizophrenia research","volume":"39","author":"van den Buuse","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"key":"R42-20230910","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fpsyt.2013.00157","article-title":"Pharmacological Interventions for the MATRICS cognitive domains in schizophrenia: What\u2019s the evidence?","volume":"4","author":"Vingerhoets","year":"2013","journal-title":"Front Psychiatry"},{"key":"R43-20230910","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","article-title":"Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia","volume":"122","author":"Young","year":"2009","journal-title":"Pharmacol Ther"},{"key":"R44-20230910","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.neubiorev.2008.04.004","article-title":"Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval","volume":"32","author":"Winters","year":"2008","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008877-201606000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T06:40:44Z","timestamp":1748673644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008877-201606000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000200","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}